Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Real-World Evidence Highlights Need for Worldwide Access
Authors:
Open Access
- 1 July 2024
- journal article
- editorial
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 21 (7) , 1003-1004
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- International disparities in diagnosis and treatment access for cystic fibrosisPediatric Pulmonology, 2024
- Cystic fibrosis in Europe: improved lung function and longevity – reasons for cautious optimism, but challenges remainEuropean Respiratory Journal, 2024
- Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least oneF508delallele: 144-week interim results from a 192-week open-label extension studyEuropean Respiratory Journal, 2023
- Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older – The RECOVER TrialAmerican Journal of Respiratory and Critical Care Medicine, 2023
- Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trialsThe Lancet Respiratory Medicine, 2022
- Dose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosisJournal of Cystic Fibrosis, 2022
- Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical TrialAmerican Journal of Respiratory and Critical Care Medicine, 2022
- Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosisJournal of Cystic Fibrosis, 2022
- Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2021
- Longitudinal effects of ivacaftor and medicine possession ratio in people with the Gly551Asp mutation: a 5-year studyThorax, 2021